Lambert-Eaton syndrome in neoplastic disease
ICD-10 G73.1 is a billable code used to indicate a diagnosis of lambert-eaton syndrome in neoplastic disease.
Lambert-Eaton syndrome (LES) is a rare autoimmune disorder characterized by muscle weakness and fatigue due to impaired release of acetylcholine at the neuromuscular junction. It is often associated with neoplastic diseases, particularly small cell lung cancer (SCLC). In LES, antibodies target voltage-gated calcium channels on presynaptic nerve terminals, leading to decreased calcium influx and reduced acetylcholine release. Clinically, patients may present with proximal muscle weakness, autonomic dysfunction, and ocular symptoms. The weakness typically improves with repeated muscle use, which is a distinguishing feature from myasthenia gravis. Diagnosis is confirmed through clinical evaluation, serological tests for anti-VGCC antibodies, and electromyography (EMG) showing a characteristic incremental response to repetitive stimulation. Treatment often involves addressing the underlying malignancy, immunotherapy, and symptomatic management. Understanding the relationship between LES and neoplastic disease is crucial for accurate diagnosis and coding.
Detailed clinical history, neurological examination findings, and results of serological tests.
Patients presenting with unexplained muscle weakness, particularly in the context of a known malignancy.
Ensure clear documentation of the relationship between symptoms and the underlying neoplastic disease.
Documentation of the cancer diagnosis, treatment plans, and any neurological evaluations performed.
Patients with small cell lung cancer presenting with new-onset muscle weakness.
Coordination with neurology for comprehensive patient management and accurate coding.
Used to evaluate neuromuscular junction function in patients suspected of having Lambert-Eaton syndrome.
Document the rationale for EMG, findings, and correlation with clinical symptoms.
Neurology specialists should ensure comprehensive documentation of EMG results.
Lambert-Eaton syndrome is primarily caused by autoantibodies against voltage-gated calcium channels, leading to impaired neurotransmitter release at the neuromuscular junction.
Diagnosis is made through clinical evaluation, serological testing for anti-VGCC antibodies, and electromyography showing characteristic incremental response.
Lambert-Eaton syndrome is often associated with neoplastic diseases, particularly small cell lung cancer, and may improve with treatment of the underlying malignancy.
